Söndag 16 November | 12:00:06 Europe / Stockholm

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2024-04-03 10:49:30

Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company's research demonstrating that SOL-116 inhibits the growth of cancer cells by blocking the target protein BSSL. Additionally, studies on breast cancer patients indicate that high expression of BSSL correlates with a poor prognosis and shorter survival.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/04/lipum-seeks-patent-protecting-inflammation-driven-cancer-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se